Overview of sacituzumab tirumotecan
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is making significant strides in the field of oncology with their anti-TROP2 antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT). Recently, the company announced that it will present important findings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. This upcoming presentation is set to unveil noteworthy results from their Phase 1/2 KL264-01/MK-2870-001 study, which evaluates the efficacy and safety of sac-TMT for patients diagnosed with advanced urothelial carcinoma (UC).
Study Highlights
The study focuses on patients with unresectable, locally advanced, or metastatic UC who have shown progression after standard therapies. The treatment regimen involves administering sac-TMT at a dose of 5 mg/kg every two weeks. A total of 49 patients were treated, providing a substantial data pool for analysis.
Profile of Participants
The study included patients with a histological or cytological diagnosis of locally advanced or metastatic UC. Each participant had a documented history of disease progression following at least one prior line of platinum-based therapy, along with treatment involving anti-PD-(L)1 therapy. The ages of participants ranged with a median age of 62 for those receiving sac-TMT as second-line treatment, while the median for third-line and beyond treatment was 61. Notably, the majority of the participants identified as Asian.
Efficacy Results
Among the findings shared, the overall objective response rate (ORR) across the participant group was reported at 31%. Specifically, this included 45% for those in the second-line group and 26% in the third-line or higher group. Further detailed efficacy results highlight:
- 5 complete responses (CR) noted in the second-line group.
- 10 partial responses (PR) observed in the third-line group.
- Stable disease (SD) was recorded in 27% of the second-line participants and 45% of the third-line cohort.
Safety Profile
The safety data obtained noted that during the trial, 59% of patients experienced grade ?3 treatment-related adverse events (TRAEs). The most observed adverse effects included anemia and decreased neutrophil counts. Importantly, no grade 5 TRAEs were reported, and most adverse events were manageable, allowing for continued treatment.
About sac-TMT
Sacituzumab tirumotecan serves as a pivotal product in Kelun-Biotech's portfolio, showcasing potential in treating advanced solid tumors. This innovative therapy utilizes a proprietary linker to efficiently deliver a topoisomerase I inhibitor payload directly to the cancer cells. With its targeted mechanism, sac-TMT can induce significant damage to tumor cell DNA, facilitating both direct and bystander effects in the tumor microenvironment.
Regulatory Advancements
The National Medical Products Administration has already approved sac-TMT for use in advanced triple negative breast cancer and is considering additional applications for other cancer indications. This regulatory progress highlights the potential wide-reaching benefits of sac-TMT in addressing critical cancer treatment needs.
About Kelun-Biotech
Kelun-Biotech is a key player under the umbrella of Kelun Pharmaceutical, focusing on innovative drug development and commercialization. The company is dedicated to advancing treatments in solid tumors and complex diseases, demonstrating commitment through over 30 ongoing drug projects. Currently, they boast an impressive ADC platform, OpitDC™, reinforcing their position as a leader in the global biomedical industry.
Frequently Asked Questions
What is sacituzumab tirumotecan?
Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting advanced solid tumors, primarily used for treating urothelial carcinoma.
What were the results of the recent study presented by Kelun-Biotech?
The study reported an overall objective response rate of 31% with safety data indicating manageable treatment-related adverse events.
Which patients were eligible for the sac-TMT study?
Eligible patients had advanced stages of urothelial carcinoma that progressed after receiving previous therapies.
What safety concerns were noted in the study?
Grade ?3 treatment-related adverse events were observed in 59% of patients, with anemia being the most common.
How does sac-TMT work?
Sac-TMT targets TROP2 on tumor cells, delivering a potent payload that damages DNA, leading to cancer cell death.
